Dysfunctional Brain Networks and Genetic Risk for Schizophrenia: Specific Neurotransmitter Systems

CNS Neuroscience and Therapeutics

Volumn 17, Issue 2, 2011, Pages 89-96

  Hirvonen, Jussi ^a,b   Hietala, Jarmo ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Dopamine; Genetics; Positron emission tomography; Schizophrenia

Indexed keywords

CANNABIS; DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROTRANSMITTER; SEROTONIN; SEROTONIN 1A RECEPTOR;

CHILD ABUSE; DISEASE PREDISPOSITION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; IN VIVO STUDY; MEDICAL LITERATURE; PATHOPHYSIOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSOCIAL DISORDER; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79952680751     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00223.x     Document Type: Review

References (115)

1. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull 2008;34:1066-1082.
2. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005;10:40-68; image 45.
3. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008;31:234-242.
4. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull 2009;35:549-562.
5. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.
6. Tost H, Alam T, Meyer-Lindenberg A. Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 2010;34:689-700.
7. Goldman-Rakic PS, Muly EC, 3rd, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000;31:295-301.
8. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci 2003;1003:138-158.
9. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-1192.
10. Tsuang M. Schizophrenia: Genes and environment. Biol Psychiatry 2000;47:210-220.
11. Owen MJ, Craddock N, O'Donovan MC. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 2010;67:667-673.
12. Cannon TD, van Erp TG, Bearden CE, et al. Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions. Schizophr Bull 2003;29:653-669.
13. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006;7:818-827.
14. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.
15. Cannon TD. Clinical and genetic high-risk strategies in understanding vulnerability to psychosis. Schizophr Res 2005;79:35-44.
16. Whalley HC, Whyte MC, Johnstone EC, Lawrie SM. Neural correlates of enhanced genetic risk for schizophrenia. Neuroscientist 2005;11:238-249.
17. Kaymaz N, van Os J. Heritability of structural brain traits an endophenotype approach to deconstruct schizophrenia. Int Rev Neurobiol 2009;89:85-130.
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-1539.
19. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423-451.
20. Skinbjerg M, Liow JS, Seneca N, et al. D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model. Neuroimage 2010;50:1402-1407.
21. Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995;346:1130-1131.
22. Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 1999;35:41-50.
23. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 1994;91:11651-11654.
24. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997;23:167-174.
25. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004;61:134-142.
26. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000;100:1-11.
27. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999;46:681-688.
28. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-271.
29. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996;93:9235-9240.
30. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997;94:2569-2574.
31. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998;155:761-767.
32. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 1999;46:56-72.
33. Abi-Dargham A, Kegeles LS, Zea-Ponce Y, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004;55:1001-1006.
34. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. Am J Psychiatry 2004;161:398-413.
35. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-8109.
36. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010;67:231-239.
37. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009;65:1091-1093.
38. Laakso A, Vilkman H, Alakare B, et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000;157:269-271.
39. Wong DF, Wagner HN, Jr., Tune LE, et al.Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563.
40. Crawley JC, Owens DG, Crow TJ, et al. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 1986;2:224-225.
41. Tune LE, Wong DF, Pearlson G, et al. Dopamine D2 receptor density estimates in schizophrenia: A positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993;49:219-237.
42. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 1990;47:213-219.
43. Hietala J, Syvalahti E, Vuorio K, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-123.
44. Martinot JL, Peron-Magnan P, Huret JD, et al. Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990;147:44-50.
45. Martinot JL, Paillere-Martinot ML, Loc'h C, et al. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991;158:346-350.
46. Martinot JL, Paillere-Martinot ML, Loc'h C, et al. Central D2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 1994;164:27-34.
47. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994;164:16-26.
48. Nordstrom AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res 1995;61:67-83.
49. Okubo Y, Suhara T, Suzuki K, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-636.
50. Knable MB, Egan MF, Heinz A, Gorey J, Lee KS, Coppola R, Weinberger DR. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [123I]-iodobenzamide SPECT study. Br J Psychiatry 1997;171:574-577.
51. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: A dual-isotope SPECT study. Am J Psychiatry 2004;161:1496-1498.
52. Corripio I, Perez V, Catafau AM, Mena E, Carrio I, Alvarez E. Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage 2006;29:662-666.
53. Kessler RM, Woodward ND, Riccardi P, et al. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 2009;65:1024-1031.
54. Kegeles LS, Slifstein M, Xu X, et al. Striatal and extrastriatal dopamine D(2)/D(3) receptors in schizophrenia evaluated with [(18)F]fallypride positron emission tomography. Biol Psychiatry 2010;68:634-641.
55. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998;42:211-221.
56. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: A case for a common site of action of antipsychotics. Trends Pharmacol Sci 1998;19:136-140.
57. Suhara T, Okubo Y, Yasuno F, et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 2002;59:25-30.
58. Yasuno F, Suhara T, Okubo Y, et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 2004;161:1016-1022.
59. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: A PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003;6:361-370.
60. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 2003;8:453-455.
61. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, Husso M, Tiihonen J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006;256:382-387.
62. Lehrer DS, Christian BT, Kirbas C, et al. (18)F-Fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res 2010;122:43-52.
63. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 2002;159:761-767.
64. Abi-Dargham A, Mawlawi O, Lombardo I, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002;22:3708-3719.
65. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003;9:404-416.
66. Catafau AM, Searle GE, Bullich S, et al. Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors. J Cereb Blood Flow Metab 2010;30:985-993.
67. Abi-Dargham A, Xu XY, Thompson JL, et al. Effect of antipsychotic treatment on cortical D1 receptors. Neuroimage 2010;52:S41-S41.
68. Slifstein M, Kolachana B, Simpson EH, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 2008;13:821-827.
69. Kosaka J, Takahashi H, Ito H, et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sci 2010;86:814-818.
70. Frankle WG, Narendran R, Huang Y, et al. Serotonin transporter availability in patients with schizophrenia: A positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 2005;57:1510-1516.
71. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 2010;67:9-16.
72. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 1991;48:355-363.
73. Tauscher J, Kapur S, Verhoeff NP, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002;59:514-520.
74. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y. Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 2004;55:439-444.
75. Frankle WG, Lombardo I, Kegeles LS, et al. Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: A positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology 2006;189:155-164.
76. Huttunen J, Heinimaa M, Svirskis T, et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 2008;63:114-117.
77. Fusar-Poli P, Howes OD, Allen P, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: A multimodal imaging study. Arch Gen Psychiatry 2010;67:683-691.
78. Stone JM, Howes OD, Egerton A, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of Psychosis. Biol Psychiatry 2010;68:599-602.
79. Valli I, Howes O, Tyrer P, McGuire P, Grasby PM. Longitudinal PET imaging in a patient with schizophrenia did not show marked changes in dopaminergic function with relapse of psychosis. Am J Psychiatry 2008;165:1613-1614.
80. Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000;96:451-474.
81. Hirvonen J, van Erp TG, Huttunen J, et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 2006;163:1747-1753.
82. Hirvonen J, van Erp TG, Huttunen J, et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 2005;62:371-378.
83. Hirvonen J, van Erp TG, Huttunen J, et al. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 2006;146:13-20.
84. Kaprio J, Koskenvuo M. Genetic and environmental factors in complex diseases: The older Finnish Twin Cohort. Twin Res 2002;5:358-365.
85. Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998;55:67-74.
86. Lee KJ, Lee JS, Kim SJ, et al. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand 2008;118:200-208.
87. Brunelin J, d'Amato T, Van Os J, Costes N, Suaud Chagny MF, Saoud M. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 2010;181:130-135.
88. Farde L, Hall H, Pauli S, Halldin C. Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man. Synapse 1995;20:200-208.
89. Puig MV, Watakabe A, Ushimaru M, Yamamori T, Kawaguchi Y. Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors. J. Neurosci. 2010;30:2211-2222.
90. Hurlemann R, Matusch A, Kuhn KU, et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 2008;195:579-590.
91. Pinborg LH, Arfan H, Haugbol S, et al. The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. Neuroimage 2008;40:1175-1180.
92. Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog. Neurobiol. 2009;88:17-31.
93. Parsey RV, Ogden RT, Miller JM, et al. Higher serotonin 1A binding in a second major depression cohort: Modeling and reference region considerations. Biol. Psychiatry 2010;68:170-178.
94. Bertolino A, Knable MB, Saunders RC, et al. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 1999;45:660-667.
95. Bertolino A, Breier A, Callicott JH, et al. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000;22:125-132.
96. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 2000;48:627-640.
97. Cannon TD, Thompson PM, van Erp TG, et al. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci U S A 2002;99:3228-3233.
98. Cannon TD, Huttunen MO, Lönnqvist J, et al. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 2000;67:369-382.
99. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain. Synapse 1989;3:96-97.
100. Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V. Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophr Res 2008;100:302-307.
101. Hirvonen M, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol Psychiatry 2005;10:889.
102. Glatt SJ, Faraone SV, Tsuang MT. Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol Psychiatry 2003;8:911-915.
103. Pohjalainen T, Cravchik A, Gejman PV, et al. Antagonist binding characteristics of the Ser311 - >Cys variant of human dopamine D2 receptor in vivo and in vitro. Biochem Biophys Res Commun 1997;232:143-146.
104. Wong AH, Buckle CE, Van Tol HH. Polymorphisms in dopamine receptors: What do they tell us? Eur J Pharmacol 2000;410:183-203.
105. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Vall 08/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922.
106. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry 2005;10:765-770.
107. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 2003;23:2008-2013.
108. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat Neurosci 2005;8:594-596.
109. Hirvonen MM, Nagren K, Rinne JO, Pesonen U, Vahlberg T, Hagelberg N, Hietala J. COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo. Mol Imaging Biol 2010;12:192-197.
110. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr. Bull. 2008;34:1111-1121.
111. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007;370:319-328.
112. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11-10.
113. Caspi A, Moffitt T, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 2005;57:1117-1127.
114. Henquet C, Rosa A, Krabbendam L, et al. An experimental study of catechol-O-methyltransferase Val158Met moderation of Δ-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748-2757.
115. Bossong MG, van Berckel BNM, Boellaard R, et al. Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2008;34:759-766.